GURUFOCUS.COM » STOCK LIST » Oceania » Australia » ASX » Vectus Biosystems Ltd (ASX:VBS) » Definitions » Debt-to-Equity
Switch to:

Vectus Biosystems (ASX:VBS) Debt-to-Equity

: 0.00 (As of Dec. 2023)
View and export this data going back to 2016. Start your Free Trial

Vectus Biosystems's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was A$0.00 Mil. Vectus Biosystems's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was A$0.00 Mil. Vectus Biosystems's Total Stockholders Equity for the quarter that ended in Dec. 2023 was A$2.37 Mil. Vectus Biosystems's debt to equity for the quarter that ended in Dec. 2023 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Vectus Biosystems's Debt-to-Equity or its related term are showing as below:

ASX:VBS' s Debt-to-Equity Range Over the Past 10 Years
Min: -10.9   Med: -1.28   Max: 0.02
Current: 0.03

During the past 8 years, the highest Debt-to-Equity Ratio of Vectus Biosystems was 0.02. The lowest was -10.90. And the median was -1.28.

ASX:VBS's Debt-to-Equity is ranked better than
80.73% of 1095 companies
in the Biotechnology industry
Industry Median: 0.14 vs ASX:VBS: 0.03

Vectus Biosystems Debt-to-Equity Historical Data

The historical data trend for Vectus Biosystems's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vectus Biosystems Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Debt-to-Equity
Premium Member Only Premium Member Only Premium Member Only -0.53 -1.28 -2.72 -1.70 0.02

Vectus Biosystems Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-Equity Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.51 -1.70 - 0.02 -

Competitive Comparison

For the Biotechnology subindustry, Vectus Biosystems's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vectus Biosystems Debt-to-Equity Distribution

For the Biotechnology industry and Healthcare sector, Vectus Biosystems's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Vectus Biosystems's Debt-to-Equity falls into.



Vectus Biosystems Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Vectus Biosystems's Debt to Equity Ratio for the fiscal year that ended in Jun. 2022 is calculated as

Vectus Biosystems's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vectus Biosystems  (ASX:VBS) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Vectus Biosystems Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Vectus Biosystems's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Vectus Biosystems (ASX:VBS) Business Description

Traded in Other Exchanges
N/A
Address
3-11 Primrose Avenue, Rosebery, Sydney, NSW, AUS, 2018
Vectus Biosystems Ltd is an emerging biotechnology company based in Sydney, Australia. The company is in the process of developing a treatment for fibrosis and high blood pressure, which includes heart, kidney, and liver diseases. The company has also developed a technology aimed at improving the speed and accuracy of measuring the amount of DNA and RNA in samples tested in laboratories.

Vectus Biosystems (ASX:VBS) Headlines

No Headlines